Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Zhejiang DTRM Biopharma
Oncternal Therapeutics, Inc
Celgene
Vifor Pharma
miRagen Therapeutics, Inc.
Incyte Corporation
Spectrum Pharmaceuticals, Inc
Gilead Sciences
miRagen Therapeutics, Inc.
Seagen Inc.
Ariad Pharmaceuticals
HemaQuest Pharmaceuticals Inc.